STOCK TITAN

Longevity Health expects Q3 loss of about $2.5M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

Longevity Health Holdings, Inc. (XAGE) expects to file its Form 10-Q for the quarter ended September 30, 2026 within the five-calendar-day extension. The auditors’ review was delayed by a late valuation report on convertible notes; a Microsoft 365 disruption on November 12, 2026 further interrupted coordination.

Preliminary results show a net loss of approximately $2.5 million, versus approximately $1.4 million a year earlier, and net sales of approximately $0.3 million, versus $0.4 million. The loss includes approximately $1.9 million in non-cash charges related to convertible notes issued in settlement of litigation, partly offset by a $1.0 million decrease in operating expenses. Results remain subject to auditor review and may differ materially.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • None.

Negative

  • Major pointThird-quarter net loss was approximately $2.5 million, versus approximately $1.4 million a year earlier.
  • Moderate pointNet sales were approximately $0.3 million, compared with $0.4 million a year earlier.
Expected net loss Approximately $2.5 million Three months ended September 30, 2026; preliminary
Prior-year net loss Approximately $1.4 million Three months ended September 30, 2025
Net sales Approximately $0.3 million Three months ended September 30, 2026; preliminary
Prior-year net sales $0.4 million Three months ended September 30, 2025
Non-cash charges related to convertible notes Approximately $1.9 million Three months ended September 30, 2026
Loss on litigation settlement $0.9 million Recognized when the notes were recorded at fair value
Loss from change in fair value of derivative liabilities $1.0 million Three months ended September 30, 2026
Decrease in operating expenses $1.0 million Compared with the prior-year period; mainly in general and administrative expenses
convertible notes financial
"final report of the third-party valuation expert for its convertible notes"
Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.
derivative liabilities financial
"change in fair value of the related derivative liabilities"
Derivative liabilities are obligations a company records when it owes money under financial contracts whose value depends on something else, like interest rates, stock prices, or currencies. Think of them as bets or insurance policies that can create future cash payments; they matter to investors because they can cause sudden changes in a company’s reported debt, profits and cash flow and reveal exposure to market risks that could affect valuation.
fair value financial
"notes were recorded at fair value"
Fair value is an estimate of what an asset or company is really worth today, derived from expected future earnings, comparable market prices and other relevant facts—like agreeing a price for a used car after checking mileage, condition and similar listings. Investors use fair value to decide whether a stock looks overpriced or undervalued, which helps guide buy, hold or sell decisions and sets expectations for potential returns and risk.
Rule 10-01(d) of Regulation S-X regulatory
"review ... as required by Rule 10-01(d) of Regulation S-X"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What results did XAGE expect for the third quarter of 2026?

Longevity Health Holdings expected a net loss of approximately $2.5 million for the three months ended September 30, 2026, versus approximately $1.4 million a year earlier. Net sales were expected to be approximately $0.3 million, compared with $0.4 million. These preliminary results are subject to the independent accounting firm's review and may differ materially.

Why was XAGE's third-quarter 2026 report delayed?

The company said its independent accounting firm's review was delayed after it received the final third-party valuation report for its convertible notes late in the quarterly close. A Microsoft 365 service disruption on November 12, 2026 interrupted email and document access for the company and its outside advisers, further delaying coordination.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

(Check one):

☐ Form 10-K   ☐ Form 20-F   ☐ Form 11-K   ☑ Form 10-Q   ☐ Form 10-D   ☐ Form N-CEN

 

☐ Form N-CSR

 

 

For Period Ended:

09/30/2026

 

 

☐   Transition Report on Form 10-K

 

 

☐   Transition Report on Form 20-F

 

 

☐   Transition Report on Form 11-K

 

 

☐   Transition Report on Form 10-Q

 

 

For the Transition Period Ended:

 

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 


 

PART I — REGISTRANT INFORMATION

 

Longevity Health Holdings, Inc.


Full Name of Registrant

 


Former Name if Applicable

 

2403 Sidney Street, Suite 300


Address of Principal Executive Office (Street and Number)

 

Pittsburgh, PA 15203


City, State and Zip Code

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

 

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 


 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

Longevity Health Holdings, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense.

 

The review by the Company's independent registered public accounting firm, as required by Rule 10-01(d) of Regulation S-X, was delayed because the Company received the final report of the third-party valuation expert for its convertible notes late in the quarterly close. That valuation drives the accounting for the notes and their related derivative liabilities, which involves complex accounting judgments that the Company’s auditors must evaluate.

 

In addition, a widespread Microsoft 365 service disruption on November 12, 2026 interrupted email and document access for the Company and its outside advisors, further delaying coordination during the final days before the filing deadline.

 

The Company expects to file the Form 10-Q within the five-calendar-day extension period provided by Rule 12b-25.

 

 

PART IV — OTHER INFORMATION

 

(1)

Name and telephone number of person to contact in regard to this notification

 

Bryan Cassaday

 

412

 

894-8248

 

(Name)

 

(Area Code)

 

(Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).          Yes ☑ No ☐

 


 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☑ No ☐

 

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

The Company expects to report a net loss of approximately $2.5 million for the three months ended September 30, 2026, compared with a net loss of approximately $1.4 million for the three months ended September 30, 2025. The increase is primarily due to approximately $1.9 million of non-cash charges related to the convertible notes the Company issued in settlement of litigation: a $0.9 million loss on litigation settlement recognized when the notes were recorded at fair value, and a $1.0 million loss from the change in fair value of the related derivative liabilities. These charges were partially offset by a $1.0 million decrease in operating expenses, mainly in general and administrative expenses. Net sales were approximately $0.3 million, compared with $0.4 million in the prior-year period. These results are preliminary and subject to completion of the review of the Company’s interim financial statements by its independent registered public accounting firm. Actual results may differ materially from these estimates.

2


Longevity Health Holdings, Inc.


(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: 

11/16/2026

 

By:

/s/ Bryan J. Cassaday

Bryan J. Cassaday

Chief Financial Officer

 

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

 

ATTENTION

 

 

 

Intentional misstatements or omissions of fact constitute Federal CriminalViolations (See 18 U.S.C. 1001).

 

GENERAL INSTRUCTIONS

 

1.

This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.

 

2.

One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission files.

 

3.

A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.

 

4.

Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.

 

5.

Interactive data submissions. This form shall not be used by electronic filers with respect to the submission or posting of an Interactive Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the time period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter).

 

 

 

3

Keep reading